Clinical Performance of Reveal G4 Rapid HIV-1 Antibody Test

HIV Infections Clinical Trial

Official title:

Clinical Performance of Reveal G4 Rapid HIV-1 Antibody Test for the Detection of HIV-1 Antibodies in Fingerstick and Venous Whole Blood Samples

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02190578
• Other study ID #: MCP005
• Status: Completed
• Phase: N/A
• First received: July 11, 2014
• Last updated: April 23, 2015
• Start date: July 2014
• Est. completion date: March 2015

Study information

• Verified date: July 2014
• Source: MedMira Laboratories Inc.
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

To determine the efficacy of an improved rapid diagnostic test using venous whole blood and fingerstick whole blood. The clinical performance of Reveal G4 Rapid HIV-1 Antibody Test will be determined by comparing the results with patient infected status for HIV-1 (human immunodeficiency virus type 1).

The study will consist of a single one-hour visit, at which time blood samples will be collected and tested with the investigational device (Reveal G4) and FDA approved comparator assays for detection of HIV-1 antibodies.

Description:

This clinical trial is a multi-center study to assess the performance characteristics of a rapid in vitro diagnostic assay, the Reveal G4 Rapid HIV-1 Antibody Test (Reveal G4). Specifically, the objective of this study is to determine the sensitivity and specificity of Reveal G4 in finger stick and venous whole blood, relative to FDA approved reference assays for the detection of HIV-1 antibodies.

Approximately 1500-2000 subjects in total will be enrolled in the study across all sites, into three different study populations. Population 1 will be comprised of at least 500 subjects from a population at risk of infection with HIV. Population 2 will be comprised of at least 500 subjects that are known HIV positive individuals. Population 3 will be comprised of at least 500 subjects from a population at low risk of HIV infection. Reveal G4 will be used to test fingerstick whole blood and venous whole blood samples from all study subjects. For enrolled subjects in Populations 1 and 3, who are of unknown HIV antibody status, a plasma sample prepared from the venous whole blood sample will also be tested with an algorithm of FDA-approved assays for the detection of HIV-1 antibodies. For Population 2 subjects who are known HIV-positive individuals, results of previous HIV tests will be obtained from the subjects' medical records. The sensitivity and specificity of Reveal G4 will be determined in fingerstick and venous whole blood relative to HIV-1 antibody status as determined by an algorithm of FDA-approved assays.

The primary analysis will involve comparison of Reveal G4 results for anti-HIV-1 in each sample matrix (fingerstick whole blood and venous whole blood) with the subject's HIV-1 antibody status as determined by FDA-approved assays. Based on the above, the sensitivity and specificity of Reveal G4 will be determined with corresponding two-sided 95% confidence intervals for both fingerstick and venous whole blood.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 1649
• Est. completion date: March 2015
• Est. primary completion date: March 2015
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 13 Years and older

Eligibility

Inclusion Criteria:

• All subjects must be at least 18 years of age, able to sign consent form, complete the risk assessment questionnaire, and provide the required blood samples: fingerstick sample (1 drop), venous whole blood sample (1 K2 EDTA tube).

• Population 1 - Individuals at risk of HIV infection (n = 500) Subjects must meet have at least one risk factor for infection with HIV

• Population 2 - Known HIV-1 positive individuals (n = 500) Subjects must be a known HIV-positive individual (previous positive HIV test result)

• Population 3 - Individuals at low risk of HIV infection (n = 500) Subjects must not have any risk factors for infection with HIV

Exclusion Criteria:

• Subjects do not meet inclusion criteria

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic

Related Conditions & MeSH terms

• HIV Infections

Intervention

Device:
• Reveal G4
All subjects tested with the investigational device, Reveal G4, plus with an algorithm of approved assays for HIV.

Locations

Country	Name	City	State
United States	Therafirst Medical Center	Fort Lauderdale	Florida
United States	Preventive Medicine, University of Southern California (Los Angeles)	Los Angeles	California
United States	New York City Department of Health and Mental Hygiene	Queens	New York
United States	Biological Specialty Corporation	Reading	Pennsylvania

Sponsors (1)

Lead Sponsor	Collaborator
MedMira Laboratories Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Determine clinical performance of Reveal G4	To determine the clinical performance of Reveal G4 with fingerstick and venous whole blood relative to the HIV-1 infected status of the patient	At single study visit (one hour)	No